NYR 9.26% 5.9¢ nyrada inc.

Ann: Investor Roadshow Presentation, page-5

  1. 2,011 Posts.
    lightbulb Created with Sketch. 455
    No no...What I meant was that despite Merck being the potential to market...the market is big enough for multiple players...

    What I am really interested in if Oral PCSK9 has a potential to replace statins...Initial results are positive not only as an add on to Statin but also stand alone..

    NYX-PCSK9i reduced cholesterol by almost half vs. Lipitor® alone (27%)
    Reduced cholesterol by 65% when dosed with Lipitor®
    Equivalent cholesterol reduction to injectable PSCK9 inhibitor Praluent®

    The challenge with Injectable PCSK9 is its very expensive relative to the cheap statins and also a lot of people don't like injectables..

    the cost of manufacturing for Oral PSCK9 is way cheaper than injectables and if the trials continue to be positive....Do PCSK 9's have the potential to replace statin as a stand alone therapy as the potential is enormous....I know that PCSK9's only came to market about 5 years ago compare to Statins but in next 5-7 years, the entire landscape can change when PCSK9's have enough long term safety data...

    With orals PCSK9's so cheap to produce with better efficacy, I struggle to see why they can't be first line!





 
watchlist Created with Sketch. Add NYR (ASX) to my watchlist
(20min delay)
Last
5.9¢
Change
0.005(9.26%)
Mkt cap ! $10.75M
Open High Low Value Volume
5.7¢ 5.9¢ 5.7¢ $4.571K 80K

Buyers (Bids)

No. Vol. Price($)
1 172711 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.9¢ 804500 1
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.